6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trialJoo‐Yong Hahn, Young Bin Song, Ju Hyeon Oh et al.|The Lancet|2018Cited by 372
Ischemic Postconditioning During Primary Percutaneous Coronary InterventionJoo‐Yong Hahn, Hyeon‐Cheol Gwon, Young Bin Song et al.|Circulation|2013Cited by 166
Transforming Growth Factor-β1 Is a Molecular Target for the Peroxisome Proliferator-Activated Receptor δHyo Jung Kim, Han Geuk Seo, Sun Ah Ham et al.|Circulation Research|2007Cited by 77
Peroxisome Proliferator-Activated Receptor δ Regulates Extracellular Matrix and Apoptosis of Vascular Smooth Muscle Cells Through the Activation of Transforming Growth Factor-β1/Smad3Hyo Jung Kim, Han Geuk Seo, Min Young Kim et al.|Circulation Research|2009Cited by 51
Expression of a Peroxisome Proliferator-Activated Receptor γ1 Splice Variant that Was Identified in Human Lung Cancers Suppresses Cell Death Induced by Cisplatin and Oxidative StressHyo Jung Kim, Han Geuk Seo, Jin‐Yong Hwang et al.|Clinical Cancer Research|2007Cited by 33